New research in mice indicates that long-term pyruvate supplements increase the brain’s energy reserves, and reduce the effects of aging on memory and exploratory behaviors.
Ask the experts: should we screen for Alzheimer’s disease? (Part 3: Current diagnostics & future biomarkers)
Part 2 of our first ‘Ask the experts’ discusses current diagnostics for Alzheimer’s disease and future opportunities in the form of biomarkers.
New research shows that ‘hyperactive’ movement may have a positive effect on working memory in children with attention deficit hyperactivity disorder.
The Four Mountains Test provides a potentially reliable, cheap and simple diagnosis method for Alzheimer’s disease. We talked to Ruth Wood to find out more about the research currently ongoing with the test.
A new study suggests that persistent neurological problems in Ebola survivors are common.
More effective biomarkers are desperately needed for early diagnosis of Alzheimer’s disease in the clinic. This article discusses the role of cognitive tests and neuropsychological assessments with particular focus on semantic memory decline.
Regulatory RNAs and control of epigenetic mechanisms: expectations for cognition and cognitive dysfunction
This reviews discusses recent work into the role of non-coding RNAs in the control of epigenetic mechanisms involved in cognitive function, including neuroplasticity and neuronal development. The role of non-coding RNAs in the context of disorders such as schizophrenia and Alzheimer’s disease is also considered.
Andrés Miguez & Jordi Alberch (University of Barcelona, Spain) discuss their exceptional work on the potential efficacy of the Multiple Sclerosis drug, Fingolimod, in treating cognitive deficits in Huntington’s disease.
A newly developed light-sensitive plant–human hybrid protein may effectively modulate Ca2+ channel regulation, bolstering memory formation in mice.
This article discusses the viability of the use of deep brain stimulation in the treatment of Alzheimer’s disease.